Prijzen
- 15 resultaten
Zoekresultaten
-
-
ASH abstract achievement award
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 12 dec 2021
Prijs: Prize (including medals and awards)
-
ASH abstract achievement award
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 9 dec 2022
Prijs: Prize (including medals and awards)
-
Best oral presentation
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 25 jun 2019
Prijs: National/international honour
-
Best Oral Presentation - MOSA conference 2021
Janssens, E. M. (Recipient), De Beck, L. (Recipient), Verbeke, R. (Recipient), Lentacker, I. (Recipient), Dewitte, H. (Recipient), Menu, Eline (Recipient) & Breckpot, Karine (Recipient), 23 jun 2021
Prijs: Prize (including medals and awards)
Bestand -
Best Poster Presentation
Vandewalle, Niels (Recipient), Menu, Eline (Recipient), De Bruyne, Elke (Recipient), De Veirman, Kim (Recipient), Breckpot, Karine (Recipient) & Devoogdt, Nick (Recipient), 2 feb 2024
Prijs: Prize (including medals and awards)
-
FWO travelgrant
Van der Vreken, Arne (Recipient) & Menu, Eline (Recipient), 7 feb 2024
Prijs: Other distinction
-
Hitting multiple myeloma cells from multiple angles using Galsome vaccination and immune checkpoint inhibition
Breckpot, Karine (Recipient) & Menu, Eline (Recipient), 15 dec 2019
Prijs: Fellowship awarded competitively
-
S-adenosylmethionine Biosynthesis is a Targetable Metabolic Vulnerability in Multiple Myeloma
Wang, Yanmeng (Recipient) & Menu, Eline (Recipient), 30 sep 2022
Prijs: Prize (including medals and awards)
-
Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents.
Muylaert, Catharina (Recipient), Menu, Eline (Recipient) & De Bruyne, Elke (Recipient), sep 2023
Prijs: Prize (including medals and awards)
-
TARGETING MONOCARBOXYLATE TRANSPORTER 4 REDUCES MYELOMA CELL VIABILITY IN VITRO
Oudaert, Inge (Recipient), Menu, Eline (Recipient) & Van Droogenbroeck, L. (Recipient), 3 mrt 2021
Prijs: Prize (including medals and awards)
-
Targeting of DNMT3B in the plasma cell cancer multiple myeloma disturbs cancer cell growth and clonogenicity and boosts the anti-tumor activity of the proteasome inhibitor bortezomib
Muylaert, Catharina (Recipient), Menu, Eline (Recipient) & De Bruyne, Elke (Recipient), 30 sep 2022
Prijs: Prize (including medals and awards)
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 29 jan 2021
Prijs: Prize (including medals and awards)
-
The de novo DNA methyltransferase DNMT3B: A new promising target in multiple myeloma
Muylaert, Catharina (Recipient), Menu, Eline (Recipient) & De Bruyne, Elke (Recipient), 2022
Prijs: Prize (including medals and awards)
-
The de novo DNA methyltransferase DNMT3B plays an important role in multiple myeloma cell growth, clonogenicity and drug response
Muylaert, Catharina (Recipient), Menu, Eline (Recipient) & De Bruyne, Elke (Recipient), 19 nov 2022
Prijs: Prize (including medals and awards)